Inside the exit: DPI aimed to fill gap in drug development for emerging markets

The sale of DPI-backed Kelix Bio to Mubadala Investment Company was announced in March.

3 April 2024•4 mins read
LinkedInXEmail
LinkedInXEmail

Related articles